|
New World Laboratories, Inc. |
|
|
500 Cartier Boulevard West
Laval, Quebec H7V 5B7 Canada
phone:450-781-2155
fax:
|
|
| Symbol |
Private |
| Founded |
2007 |
| Employees |
12 |
|
|
| www.nwl.net
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Specializes in the research and development of unique therapeutics and technologies for Regenerative Medicine. |
|
| Management |
Jan-Eric W. Ahlfors, CEO & CSO;
Christopher U. Missling, CBDO & CFO;
Susan Imeson, Corporate Director;
Rody Ayoubi, Director of Product Development;
Khalid Mekouar, Director of Drug Development |
| |
|
|
| |
|
| Keywords |
| regenerative medicine, regeneration, degeneration, neurodegenerative, multiple sclerosis, alzheimer's, parkinson's, stroke, traumatic brain injury, spinal cord injury, cardiac ischemia, diabetes, aging |
|
|
|
| Description |
|
New World Laboratories Inc. (NWL) develops innovative breakthrough & platform therapeutics and technologies for the upcoming Regenerative Medicine industry. The therapeutics & technologies being developed at NWL are designed to either prevent tissue degeneration and/or promote tissue regeneration. Key products and technologies include NWL-053, NWL-NSC, RMx, and NWL-LTI. |
|
| Products / Services |
NWL-053: an apoptosis modulator (Peptidomimetic Drug) that prevents cell death without causing tumor formation, is able to cross the blood-brain-barrier, and is very stable with no toxicity. Has numerous applications including Multiple Sclerosis, Alzheimer's, Parkinson's, ALS, Stroke, Cardiac Ischemia, Muscle Atrophy, and Diabetes.
NWL-NSC: neural stem-like cells that are more potent and safer than neural stem cells. These cells are produced ethically and at low cost, and can be made autologously or allogenically. Has numerous applications including Stroke, Multiple Sclerosis, ALS and Parkinson's.
RMx: a biomaterial (Device) with potent regenerative and wound healing properties that is able to present some drugs and growth factors at higher potency (growth factor presentation). Potent anti-scarring, wound healing, and tissue regeneration properties, including muscle and neuronal tissue regeneration.
NWL-LTI: living implantable tissues, including neural tissue implants, that can be used in tissue replacement therapy, or as in vitro tissue models. Autologous or allogenic.
|
|
| Technology / Differentiation |
| NWL's several breakthrough and platform technologies either prevent degeneration or support regeneration in degenerative diseases, especially neurodegenerative diseases such as Multiple Sclerosis, Alzheimer's and Parkinson's disease. Numerous patent applications have been filed, and claims have been deemed to possess Novelty, Inventive Step, and Industrial Applicability in PCT's International Preliminary Reports on Patentability. |
|
| Market / Customers |
Total Global Costs of treating degenerative diseases in 2010: $2 Trillion.
Future Markets:
Treatment of Degenerative Diseases and Tissue Loss (> $5B):
- Prevention of Tissue Loss and Degeneration ($2B)
- Tissue Regeneration, including Wound Healing ($2B)
- Tissue Replacement ($1B)
Indications: Multiple Sclerosis, Alzheimer's, Stroke, Spinal Cord Injury, Traumatic Brain Injury, Cardiac ischemia, Diabetes, Aging, etc.
Products are to be either sold by NWL (in potential partnership with other companies), or out-licensed after successful Phase I/II Clinical Trials.
|
|
| Competitors / Substitutes / Alternatives |
NWL-053: Merck M867 - pre-clinical phase peptidomimetic drug; suffers from toxicity problems.
NWL-NSC: NeuralStem Inc., ReNeuron, and StemCell Inc. - all use fetal neural stem cells that suffer from low potency, ethical and immunogenicity problems.
RMx: closest competitor is platelet-rich plasma (PRP) which has a significantly lower potency and regenerative ability than RMx in side-by-side studies.
|
|
| Status |
| NWL is at the pre-clinical stage. ~$20M has been invested (equity & grants) into developing a dominant IP position. NWL-053 and NWL-NSC could complete Phase I/IIa Clinical Trials within 2 years after financing, after which either an IPO or an out-licensing deal could be consummated. RMx (a Device) could complete Pivotal Clinical Trials and receive Market Approval within 3 years. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members